Actinium Pharmaceuticals Welcomes Dr. June Almenoff
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a cutting-edge company specializing in Antibody Radiation Conjugates (ARCs) and targeted radiotherapies, is thrilled to announce the addition of Dr. June Almenoff, M.D., Ph.D., to its Board of Directors. With over 25 years of extensive experience in drug development and senior leadership roles within the biopharma industry, Dr. Almenoff’s appointment is set to bring substantial value to the company.
Expertise in Drug Development
Dr. Almenoff's career is marked by her significant contributions to the pharmaceutical field, particularly in translational medicine and clinical development. Before joining Actinium, she held prominent positions, including President and Chief Medical Officer at Furiex Pharmaceuticals, where she played an instrumental role in the development of eluxadoline (Viberzi®). This experience has equipped her with vast knowledge in navigating the complexities of drug approval processes across various jurisdictions.
Additionally, Dr. Almenoff contributed to RedHill Biopharma, leading initiatives that recognized Talicia® as a first-line therapy for H. pylori, showcasing her track record of bringing innovative therapies to market.
Dr. Almenoff's Vision for Actinium
Chairman and CEO Andes Seth expressed optimism regarding Dr. Almenoff's capabilities, stating, "Her extensive background and track record will provide invaluable support for Actinium's strategic goals." In a recent statement, Dr. Almenoff shared her excitement about joining the Actinium Board, noting the company's pioneering work in radiotherapy, which is transforming treatment options in oncology.
The utilization of targeted radiotherapy is becoming a critical treatment strategy for patients with various cancers, and Dr. Almenoff is enthusiastic about Actinium's innovative research and development, particularly their proprietary Actinium-225 manufacturing technology.
Educational Background and Achievements
Dr. Almenoff holds a B.A. cum laude from Smith College and graduated with Alpha Omega Alpha honors from the M.D.-Ph.D. program at the Mt. Sinai School of Medicine. Her impressive academic journey includes post-graduate medical training at Stanford University Medical Center and serving on the faculty of Duke University School of Medicine, where she continues as an adjunct professor.
In addition to her corporate roles, Dr. Almenoff is an FACP Fellow of the American College of Physicians and has authored over 70 publications, solidifying her reputation as a thought leader in clinical development.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is dedicated to advancing the field of radiotherapy with its leading products aiming to improve outcomes for oncology patients who have experienced limited success with traditional treatments. Noteworthy among its offerings is Iomab-B, designed as a conditioning agent before bone marrow transplants in patients with relapsed or refractory acute myeloid leukemia (r/r AML). The company is actively seeking strategic partnerships to enhance the availability of its innovative solutions.
Another promising candidate is Actimab-A, which has shown potential in tackling r/r AML. Actinium maintains a strong collaborative relationship with the National Cancer Institute (NCI) for the development of Actimab-A and other myeloid malignancies.
Also noteworthy is Iomab-ACT, Actinium's next-generation conditioning agent aimed at improving access and outcomes for patients undergoing curative cell and gene therapies. The company is currently focused on advancing several preclinical programs targeting solid tumors and has an extensive portfolio of over 235 patents related to manufacturing isotonically Ac-225 in a cyclotron.
Frequently Asked Questions
What is Dr. June Almenoff's new role at Actinium Pharmaceuticals?
Dr. June Almenoff has been appointed to the Board of Directors of Actinium Pharmaceuticals and will provide her expertise in drug development and biopharma leadership.
What experience does Dr. Almenoff bring to the table?
Dr. Almenoff boasts over 25 years of experience in the biopharma industry, including previous roles in senior leadership and drug development at notable companies.
What is Actinium Pharmaceuticals known for?
Actinium Pharmaceuticals focuses on developing innovative Antibody Radiation Conjugates and targeted radiotherapies for oncology patients, improving treatment options.
What are some key products developed by Actinium?
Actinium's notable products include Iomab-B for acute myeloid leukemia and Actimab-A, both aimed at enhancing patient outcomes in challenging cancer cases.
How is Actinium collaborating with research entities?
Actinium is engaged with the National Cancer Institute for research and development to further enhance its treatment options and contribute to advancements in the oncology sector.
